Send the following on WhatsApp
Continue to ChatPolyphor: Krebsmedikament Balixafortide erhält in den USA "Fast Track"-Status https://www.schweizeraktien.net/blog/2018/04/19/polyphor-krebsmedikament-balixafortide-erhaelt-in-den-usa-fast-track-status-20994/